REG - Avacta Group PLC - Block Listing Six Monthly Return

AvactaAnnouncement

Mon 17:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251027:nRSa0074Fa&default-theme=true

RNS Number : 0074F  Avacta Group PLC  27 October 2025

 

 

 

 

 

Avacta Group plc

 

("Avacta" or "the Group" or "the Company")

 

Block Listing Six Monthly Return

 

LONDON AND PHILADELPHIA - October 27, 2025 Avacta Therapeutics (AIM:
AVCT, 'the Company'), a clinical stage biopharmaceutical company developing
pre|CISION(®), a tumor-activated oncology delivery platform, today makes the
following notification pursuant to Schedule Six of the AIM Rules for Companies
regarding its existing block admission arrangements:

 

 Name of applicant:                                                                  Avacta Group plc
 Name of scheme:                                                                     EMI scheme
 Period of return:                         From:                                     28 April 2025          27 October 2025
 Balance of unallotted securities under scheme(s) from previous return:              228,380
 Plus:   The amount by which the block scheme(s) has been increased since            nil
 the date of the last return (if any increase has been applied for):
 Less:   Number of securities issued/allotted under scheme(s) during                 103,822
 period (see LR3.5.7G):
 Equals:   Balance under scheme(s) not yet issued/allotted at end of period:         124,558

 

 Name of applicant:                                                                     Avacta Group plc
 Name of scheme:                                                                        LTIP/ESOS scheme
 Period of return:            From:                                                     28 April 2025            27 October 2025
 Balance of unallotted securities under scheme(s):                                      1,546,375
 Plus:   The amount by which the block scheme(s) has been increased since               6,500,000
 the date of the last return (if any increase has been applied for):
 Less:   Number of securities issued/allotted under scheme(s) during                    6,862,713
 period (see LR3.5.7G):
 Equals:   Balance under scheme(s) not yet issued/allotted at end of period:            1,183,662

  Name of contact:                                         Brian Hahn, Company Secretary
 Telephone number of contact:                              + 44 (0) 1904 217070

 

Ends-

 

 

For further information from Avacta Group plc, please contact:

 

 Avacta Group plc                                           https://avacta.com/ (https://avacta.com/)

 Christina Coughlin, Chief Executive Officer                via ICR Healthcare

 Peel Hunt (Nomad and Joint Broker)                         www.peelhunt.com (http://www.peelhunt.com)

 James Steel / Chris Golden

 Panmure Liberum (Joint Broker)                             www.panmureliberum.com (http://www.panmureliberum.com)

 Emma Earl / Will Goode / Mark Rogers

 Zeus (Joint Broker)                                        www.zeuscapital.co.uk (http://www.zeuscapital.co.uk)

 James Hornigold / George Duxberry

 Dominic King

 ICR Healthcare (Europe/UK media and investors)             avacta@icrhealthcare.com (mailto:avacta@icrhealthcare.com)

 Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert

 Investor Contact                                           renee@thrustsc.com (mailto:renee@thrustsc.com)

 Renee Leck

 THRUST Strategic Communications

 Media Contact                                              carly@thrustsc.com (mailto:carly@thrustsc.com)

 Carly Scaduto

 THRUST Strategic Communications

 

About pre|CISION(®)

 

The key aspect of pre|CISION(®) is its peptide drug conjugates (PDC)
technology.  The combination of the cancer drug and the proprietary cleavable
peptide (the PDC) is inert and incapable of entering cells and killing them
until the peptide is specifically released within the tumor. The active
payload in the pre|CISION(®) PDC is released when the PDC comes into contact
with the common tumor-associated protein, known as fibroblast activation
protein (FAP), in the tumor. The release of the payload from the
pre|CISION(®) product directly in the tumor results in higher concentration
of the drug at the tumor and lower blood and healthy tissue levels than
standard systemic administration, offering the potential to improve efficacy
and patient tolerability.

 

About Avacta - www.avacta.com (https://avacta.com/)

 

Avacta is a clinical stage life sciences company developing an innovative
proprietary drug delivery peptide drug conjugate (PDC) platform,
pre|CISION(®). The pre|CISION(®) platform uniquely enables the repurposing
of a range of oncology drugs as PDC payloads with the goal to significantly
reduce toxicity and side effects for patients by concentrating the drug
directly in the tumor.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRPPGMPUUPAGMM



            Copyright 2019 Regulatory News Service, all rights reserved